Lifecore Biomedical (LFCR) has been notified by Nasdaq that the company’s stock is expected to be added to the Nasdaq Biotech Index (NBI) as part of the annual reconstitution of the 2025 Nasdaq indexes. Lifecore’s inclusion in the Nasdaq Biotech Index will be effective prior to market open on Monday, December 22, 2025.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFCR:
- Lifecore signs CDMO master services agreement with pharma customer
- Cautious Hold Rating on Lifecore Biomedical Amid Operational Progress and Financial Risks
- Optimistic Outlook for Lifecore Biomedical: Strategic Growth and Financial Stability
- Lifecore Biomedical Reports Strong Revenue Growth
- Lifecore backs transition period revenue view $74M-$76M